Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer

This is an open-label, multicenter, Phase 1 clinical study to evaluate the bioavailability of tislelizumab subcutaneous (SC) injection in the first-line treatment of participants with advanced or metastatic non-small cell lung cancer (NSCLC). This clinical study will be divided into 2 parts: dose/injection site exploration (Part 1) and dose expansion (Part 2).

NCT Number	NCT06091943
Lead Sponsor	BeiGene
Conditions	Non-small Cell Lung Cancer
Enrollment	62 participants
Start Date	2023-11-16
Primary Completion	2025-07-31 (estimated)
Study Completion	2026-08-04 (estimated)
Updated on ClinicalTrials.gov	2026-08-12